Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

OrderlyMeds vs Remi Meds

OrderlyMeds
Graded #78

Higher grade

vs+24.000000000000007
Remi Meds
Graded #493

Lower grade

The verdict

OrderlyMeds takes it — 72.4/100 to 48.4/100.

OrderlyMeds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. OrderlyMeds is a telehealth provider selling compounded semaglutide and tirzepatide with no membership fees or hidden costs.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOrderlyMeds +58
92
34
Dose & formulationOrderlyMeds +10
64
54
Clinical oversightOrderlyMeds +28
82
54
Labs & monitoringOrderlyMeds +3
53
50
FulfillmentOrderlyMeds +12
65
53
Contract termsEven
55
55
OrderlyMeds · left barRemi Meds · right bar

The numbers

MetricOrderlyMedsRemi Meds
WeighScore72.4/10048.4/100
GradeCC
Scorecard rank#78#493
Semaglutide$74/mo (starting dose, 2-mo starter plan, new patients only, compounded)$249/mo (0.25 mg dose, compounded)
Tirzepatide$299/mo (compounded)$349/mo (2.25 mg dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
OrderlyMeds

Graded #78 · C

Strengths

  • The starter rate and the standing rate are both published, so the step-up is visible before signing up
  • No membership fees and no hidden costs, stated as such
  • The dose ladder is published: four weeks at 0.25 mg then four weeks at 0.5 mg
  • Brand-name routes are priced openly, at retail

Where it loses points

  • The $74 rate is a two-month starter plan billed as $149 up front, and it is open only to patients new to GLP-1 medication; the standing monthly rate is $149
  • Tirzepatide has no equivalent standing discount — $299/mo is the ongoing rate
  • Brand-name routes are priced at retail: Wegovy $1,839 and Zepbound $1,498
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
Remi Meds

Graded #493 · C

Strengths

  • Names its compounding pharmacy (Strive Pharmacy, Gilbert AZ) — stronger transparency than peers
  • LegitScript verification badge on the homepage
  • Publishes 503A FDCA compliance language on the tirzepatide page
  • Per-dose-tier pricing fully shown — no 'as low as' floor-only obfuscation
  • Operating corporate entity disclosed (T-C Health Co)

Where it loses points

  • No named medical director, founder, or physician on any public page
  • States served not listed — 'nationwide' claim with no per-state detail
  • Clinical care runs through Beluga Health, a network a 2026 StatNews analysis tied to many FDA-warned GLP-1 companies (Remi Meds itself not FDA-warned)
  • Year founded and corporate history are opaque
  • Two phone numbers and a secondary 'Rekindle RX' email hint at shared infrastructure

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard